Enhanced HIF Prolyl Hydroxylase Inhibitor Compositions and Methods for Treating Anemia

The present inventive concept relates to improved compositions and methods for treating anemia, including anemia secondary to or associated with chronic kidney disease, anemia associated with AIDS, and anemia associated with chemotherapy, using HIF prolyl hydroxylase inhibitor compounds and pharmaceutically acceptable salts, solvates, or hydrates thereof.

The original patent disclosed HIF prolyl hydroxylase inhibitor compounds and methods for treating anemia, but had limitations in terms of dosage, administration route, and patient population. The present inventive concept addresses these limitations by providing more efficient and targeted treatment options, including oral administration, injection, and specific dosage regimens, to increase hemoglobin levels and improve anemia treatment outcomes.

The new inventive concept comprises HIF prolyl hydroxylase inhibitor compounds selected from Formula (I), Formula (II), Formula (III), Formula (IV), or Formula (V), or compounds selected from Compound 1 to Compound 13, or pharmaceutically acceptable salts, solvates, or hydrates thereof. The compounds are administered orally or via injection in specific doses to increase hemoglobin levels, restore diurnal patterns of EPO serum levels, and improve total iron binding capacity. The inventive concept also encompasses compositions formulated as oral tablets containing 2-5 mg of the compound per tablet.

The new claims provide novel and non-obvious improvements over the original patent by introducing specific dosage regimens, administration routes, and patient populations, thereby increasing the efficiency and safety of anemia treatment. The inventive concept's novelty lies in its tailored approach to anemia treatment, which addresses the limitations of the original patent and provides more effective treatment options.

Alternative embodiments of the inventive concept may include using different formulations, such as capsules or suspensions, or exploring other administration routes, such as transdermal or intravenous delivery. Variations may also include using different HIF prolyl hydroxylase inhibitor compounds or combining them with other therapeutic agents to enhance treatment outcomes.

The inventive concept has significant commercial potential in the anemia treatment market, particularly in the areas of chronic kidney disease, AIDS, and chemotherapy-induced anemia. The targeted treatment options and improved efficacy of the inventive concept are expected to capture a substantial market share and improve patient outcomes.